ERBB2 and non-small cell lung carcinoma: The initial clinical trial (NCT03602079) of trastuzumab botidotin incorporated 35 patients suffering from locally advanced or metastatic solid tumors, including NSCLC, that were HER2+ or HER2-amplified.